COVID-19 and possible links with Parkinson\u27s disease and parkinsonism: from bench to bedside

This Viewpoint discusses insights from basic science and clinical perspectives on coronavirus disease 2019 (COVID-19)/severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection in the brain, with a particular focus on Parkinson\u27s disease. Major points include that neuropathology studies have not answered the central issue of whether the virus enters central nervous system neurons, astrocytes or microglia, and the brain vascular cell types that express virus have not yet been identified. Currently, there is no clear evidence for human neuronal or astrocyte expression of angiotensin-converting enzyme 2 (ACE2), the major receptor for viral entry, but ACE2 expression may be activated by inflammation, and a comparison of healthy and infected brains is important. In contrast to the 1918 influenza pandemic and avian flu, reports of encephalopathy in COVID-19 have been slow to emerge, and there are so far no documented reports of parkinsonism apart from a single case report. We recommend consensus guidelines for the clinical treatment of Parkinson\u27s patients with COVID-19. While a role for the virus in causing or exacerbating Parkinson\u27s disease appears unlikely at this time, aggravation of specific motor and non-motor symptoms has been reported, and it will be important to monitor subjects after recovery, particularly for those with persisting hyposmia

Data-driven analysis to understand long COVID using electronic health records from the RECOVER initiative

In this study, the authors characterise post-acute sequelae of SARS-CoV-2 (PASC) in two large cohorts based on electronic health records from the USA. They identify a broad range of PASC-related conditions which were only partially replicated across the two cohorts, indicating possible heterogeneity between populations